The company combines smart chemistry and bioscience to discover new medicines to treat diseases of the nervous system. PharmNovo’s aim has been to develop biased agonists of the delta opioid receptor (DOR). Unlike the mu opioid receptor which is the major target of conventional opioid drugs, activating the DOR does not provide good acute analgesia but produces excellent reversal of chronic pain in animal models. DOR agonists have none of the unwanted effects of conventional opioids.
- Bli medlem
- Om SwedenBIO